Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

E. P. Alessandrino, P. Bernasconi, A. Colombo, D. Caldera, G. Martinelli, P. Vitulo, L. Malcovati, C. Nascimbene, M. Varettoni, E. Volpini, C. Klersy, C. Bernasconi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalBone Marrow Transplantation
Volume25
Issue number3
Publication statusPublished - 2000

Fingerprint

Carmustine
Cell Transplantation
Hematologic Neoplasms
Blood Cells
Stem Cells
Lung
Etoposide
Melphalan
Cyclophosphamide
Steroids
Autologous Transplantation
Interstitial Lung Diseases
Prednisone
Multiple Myeloma
Hodgkin Disease
Non-Hodgkin's Lymphoma
Multivariate Analysis
Body Weight
Transplants
Incidence

Keywords

  • Autologous peripheral blood progenitor cell transplantation
  • Carmustine
  • Pulmonary toxicity

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{11f0e56a19614c069263d29b38b812a4,
title = "Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies",
abstract = "Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26{\%}) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.",
keywords = "Autologous peripheral blood progenitor cell transplantation, Carmustine, Pulmonary toxicity",
author = "Alessandrino, {E. P.} and P. Bernasconi and A. Colombo and D. Caldera and G. Martinelli and P. Vitulo and L. Malcovati and C. Nascimbene and M. Varettoni and E. Volpini and C. Klersy and C. Bernasconi",
year = "2000",
language = "English",
volume = "25",
pages = "309--313",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies

AU - Alessandrino, E. P.

AU - Bernasconi, P.

AU - Colombo, A.

AU - Caldera, D.

AU - Martinelli, G.

AU - Vitulo, P.

AU - Malcovati, L.

AU - Nascimbene, C.

AU - Varettoni, M.

AU - Volpini, E.

AU - Klersy, C.

AU - Bernasconi, C.

PY - 2000

Y1 - 2000

N2 - Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.

AB - Sixty-five patients with hematological malignancies (25 multiple myeloma, 18 Hodgkin's disease, 22 non-Hodgkin's lymphomas) who received a carmustine-based regimen followed by autologous PBPC transplantation, were studied retrospectively to evaluate the incidence of post-transplant non-infective pulmonary complications (NIPCs), risk factors predictive of NIPCs, and response to steroids. Carmustine (BCNU) given i.v. at a dose of 600 mg/m2 was combined with etoposide and cyclophosphamide in 40 patients (BCV regimen) and with etoposide and melphalan in 25 patients (BEM regimen). Seventeen of 65 patients (26%) had one episode of NIPCs. The median time to NIPCs was 90 days (52-289). Factors that increased the risk of developing NIPCs on multivariate analysis were female sex (P <0.001) and BCV regimen (P <0.05). All patients with NIPCs received prednisone at a dose of 1 mg/kg body weight for 10 days then tapered by 5 mg every two days; complete response to steroids was achieved in 15 of 17 patients; one unresponsive patient died of interstitial pneumonia, BCNU given at the dose of 600 mg/m2 is well tolerated when associated with melphalan and etoposide. In females and in patients receiving BCNU with cyclophosphamide, a BCNU dose reduction may be advisable.

KW - Autologous peripheral blood progenitor cell transplantation

KW - Carmustine

KW - Pulmonary toxicity

UR - http://www.scopus.com/inward/record.url?scp=19244370150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244370150&partnerID=8YFLogxK

M3 - Article

C2 - 10673703

AN - SCOPUS:19244370150

VL - 25

SP - 309

EP - 313

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -